Skip to main content

JAZZ Jazz Pharmaceuticals plc

Healthcare

strong quality, fair valuation.

Quality
Top tier
Valuation
Fair
Key signals
Filed revenue acceleration
237.95
237.95 Close (USD) Loading candles…

Is Jazz Pharmaceuticals plc a buy? Fundamentals and valuation first

  • Quality is top-tier. Operating margin ranks above roughly 84% of the liquid US common-stock universe. TTM ROE is about 19.6%.

  • Valuation is middle-of-pack. TTM P/E is near the 69th percentile.

  • Recent volatility is moderate. 60-day annualized volatility is near the 30th percentile. Average 20-day dollar volume is about $191.4M.

  • Signals are active now. Filed revenue acceleration currently holds; the tables below show what followed in this stock’s own history.

Watchlist

This page refreshes daily after the close. Add Jazz Pharmaceuticals plc to your watchlist to track signal changes on your next visit.

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Filed revenue acceleration

Active · now 12.590565236701057%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

11 historical occurrences (since 2018-05-08)
Average forward return after Filed revenue acceleration。20-day: Win 36.4%, Sample 11, Median -4.12%, Excess -0.65%, Beat mkt rate 36.4%；60-day: Win 50%, Sample 10, Median +1.21%, Excess -1.28%, Beat mkt rate 60%；120-day: Win 30%, Sample 10, Median -10.04%, Excess -5.56%, Beat mkt rate 30%

120 days after: historical avg -6.92%

20-day -1.41%
60-day -1.89%
120-day -6.92%
20-day
60-day
120-day
Win
36.4%
50%
30%
Sample
11
10
10
Median
-4.12%
+1.21%
-10.04%
Excess
-0.65%
-1.28%
-5.56%
Beat mkt rate
36.4%
60%
30%

Over 10 occurrences, 120-day forward avg declined 6.92%, lagged the market by 5.56 pts; win rate 30%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 64+63.9% +55.4% 100% +24.4%
20-40 You are here161+48% +95.2% 67.7% +23.1%
40-60 73-4.7% -0.5% 47.9% -21%
60-80 34+58.6% +59.8% 97.1% +22.2%
80-100 396-5.3% -8.8% 28.5% -30.9%

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 16.26, placing it in the 20.7 own-history percentile, inside the 20-40 bucket.

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
Now
+16.2%
Win rate 45.8% Excess +8%
120d
-9.7%
Win rate 30.9% Excess -18.8%
97d
+9.7%
Win rate 70.2% Excess -4.9%
225d
60-day momentum down
+68.3%
Win rate 89.6% Excess +45.3%
144d
+16.9%
Win rate 92.4% Excess +5.3%
66d
-6%
Win rate 13.8% Excess -19.6%
196d

Currently in “Cheap (own-history bottom third) × 60-day momentum up”: across 120 historical days, 120-day forward avg gained 16.2%, win rate 45.8%, beat the market by 8%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 98,702 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.12%, a 57.8% positive-return rate, and +2.76 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

13 times historically; 60-day forward avg +1.21%, win rate 53.8%, beating the market by -2.89 pts on average.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

13 times historically; 60-day forward avg -5.03%, win rate 25%, beating the market by -4.14 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

21 times historically; 60-day forward avg +3.46%, win rate 66.7%, beating the market by +1.35 pts on average.

Continue researching Jazz Pharmaceuticals plc with the evidence above.

Continue in Studio ↗

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.